P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

Lung Cancer ◽

10.1016/s0169-5002(05)80945-6 ◽

2005 ◽

Vol 49 ◽

pp. S235 ◽

Cited By ~ 9

Author(s):

C. Belani ◽

J. von Pawel ◽

A. Pluzanska ◽

V. Gorbounova ◽

E. Kaukel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283381.78585.f2 ◽

2007 ◽

Vol 2 (8) ◽

pp. S451

Author(s):

Eng-Huat Tan ◽

Tomasz Grodzki ◽

Claus-Peter Schneider ◽

Peter Zatloukal ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdn774 ◽

2009 ◽

Vol 20 (7) ◽

pp. 1249-1256 ◽

Cited By ~ 43

Author(s):

E.H. Tan ◽

J. Rolski ◽

T. Grodzki ◽

C.P. Schneider ◽

U. Gatzemeier ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial

Clinical Lung Cancer ◽

10.1016/j.cllc.2017.01.002 ◽

2017 ◽

Vol 18 (4) ◽

pp. e289-e296 ◽

Cited By ~ 10

Author(s):

Cheol-Kyu Park ◽

In-Jae Oh ◽

Kyu-Sik Kim ◽

Yoo-Duk Choi ◽

Tae-Won Jang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

BMC Cancer ◽

10.1186/s12885-016-2301-6 ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 15

Author(s):

Yan Sun ◽

Ying Cheng ◽

Xuezhi Hao ◽

Jie Wang ◽

Chengping Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8016 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8016-8016 ◽

Cited By ~ 7

Author(s):

V. Hirsh ◽

M. Boyer ◽

R. Rosell ◽

R. J. Benner ◽

D. Readett ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3-3 ◽

Cited By ~ 70

Author(s):

R. Pirker ◽

A. Szczesna ◽

J. von Pawel ◽

M. Krzakowski ◽

R. Ramlau ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.11.025 ◽

2020 ◽

Author(s):

Makoto Nishio ◽

Fabrice Barlesi ◽

Howard West ◽

Simon Ball ◽

Rodolfo Bordoni ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

Reviews on Recent Clinical Trials ◽

10.2174/15748871112079990040 ◽

2013 ◽

Vol 8 (1) ◽

pp. 23-28 ◽

Cited By ~ 4

Author(s):

Cesare Gridelli ◽

Paolo Maione ◽

Antonio Rossi

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text

O-51 Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCB) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small cell lung cancer (NSCLC): analyses in elderly patients

Lung Cancer ◽

10.1016/s0169-5002(03)91709-0 ◽

2003 ◽

Vol 41 ◽

pp. S18 ◽

Cited By ~ 18

Author(s):

Chandra P. Belani ◽

Frank V. Fossella

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

Annals of Oncology ◽

10.1093/annonc/mdy292.005 ◽

2018 ◽

Vol 29 ◽

pp. viii496 ◽

Cited By ~ 6

Author(s):

M. Seike ◽

A. Inoue ◽

S. Sugawara ◽

S. Morita ◽

Y. Hosomi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text